XML 78 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements (Collaboration Revenues - Ipsen) (Details) - USD ($)
 12 Months Ended
Dec. 29, 2017
Dec. 30, 2016
Jan. 01, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Product supply agreement revenue $ 349,008,000 $ 135,375,000 $ 34,158,000
Cost of supplied product (15,066,000) (6,552,000) (3,895,000)
Collaboration revenues under the Ipsen Collaboration Agreement 103,469,000 56,079,000 3,014,000
Collaborative arrangement with Ipsen [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Milestones achieved 45,000,000 20,000,000  
Amortization of upfront payments and deferred milestone 18,531,000 13,284,000  
Royalty revenue 3,831,000 175,000  
Development cost reimbursements 4,417,000 0  
Product supply agreement revenue 6,390,000 1,612,000  
Cost of supplied product (6,390,000) (1,555,000)  
Royalty payable to GSK on net sales by Ipsen (1,987,000) (264,000)  
Collaboration revenues under the Ipsen Collaboration Agreement $ 69,792,000 $ 33,252,000 $ 0